{"id":15541,"date":"2021-10-05T11:45:33","date_gmt":"2021-10-05T09:45:33","guid":{"rendered":"https:\/\/convergences.online\/hemato\/?p=15541"},"modified":"2021-10-05T11:45:33","modified_gmt":"2021-10-05T09:45:33","slug":"eusa-pharma-annonce-la-publication-au-journal-officiel-du-30-septembre-2021-du-remboursement-de-sa-specialite-sylvant-siltuximab","status":"publish","type":"post","link":"https:\/\/www.hematostat.net\/en\/eusa-pharma-annonce-la-publication-au-journal-officiel-du-30-septembre-2021-du-remboursement-de-sa-specialite-sylvant-siltuximab\/","title":{"rendered":"EUSA Pharma annonce la publication au Journal Officiel du 30 septembre 2021 du remboursement de sa sp\u00e9cialit\u00e9 SYLVANT\u00ae (Siltuximab)"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:calc( 1240px + 0px );margin-left: calc(-0px \/ 2 );margin-right: calc(-0px \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:0px;--awb-margin-bottom-large:0px;--awb-spacing-left-large:0px;--awb-width-medium:100%;--awb-spacing-right-medium:0px;--awb-spacing-left-medium:0px;--awb-width-small:100%;--awb-spacing-right-small:0px;--awb-spacing-left-small:0px;\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-text fusion-text-1\"><p>EUSA Pharma annonce la publication au Journal Officiel du 30 septembre 2021 du remboursement de sa sp\u00e9cialit\u00e9 SYLVANT\u00ae (Siltuximab) faisant de cette mol\u00e9cule la seule approuv\u00e9e et rembours\u00e9e en France pour le traitement des patients adultes atteints de la maladie de Castleman (MC) multicentrique, non infect\u00e9s par le virus de l&#8217;immunod\u00e9ficience humaine (VIH) et l&#8217;herp\u00e8s-virus humain 8 (HHV-8).<\/p>\n<p>La Commission de la Transparence de la Haute Autorit\u00e9 de Sant\u00e9 (HAS) avait, en date du 16 septembre 2020, rendu un avis favorable au remboursement pour cette sp\u00e9cialit\u00e9, consid\u00e9rant que \u00ab SYLVANT\u00ae (Siltuximab) apporte un service m\u00e9dical rendu (SMR) important et une am\u00e9lioration du service m\u00e9dical rendu mineure (ASMR IV) pour le traitement des patients adultes atteints de la maladie de Castleman multicentrique chez les patients adultes, non infect\u00e9s par le VIH et le HHV-8 \u00bb.<\/p>\n<p>Dans son avis, la HAS conclut que SYLVANT\u00ae (Siltuximab) est la \u00ab seule bioth\u00e9rapie \u00e0 disposer d\u2019une AMM en France dans le traitement des patients adultes atteints de cette maladie et qu\u2019elle est par cons\u00e9quent la bioth\u00e9rapie de choix dans cette indication \u00bb. Enfin, la commission octroyait un int\u00e9r\u00eat de sant\u00e9 publique (ISP) \u00e0 cette sp\u00e9cialit\u00e9.<\/p>\n<\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[21],"tags":[],"ppma_author":[442],"class_list":["post-15541","post","type-post","status-publish","format-standard","hentry","category-communique-de-presse","author-marion"],"aioseo_notices":[],"authors":[{"term_id":442,"user_id":2,"is_guest":0,"slug":"marion","display_name":"HematoStat.net (M)","avatar_url":{"url":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2024\/01\/favicon-hematoStat.png","url2x":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2024\/01\/favicon-hematoStat.png"},"first_name":"HematoStat.net (M)","last_name":"","user_url":"","description":""}],"_links":{"self":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/15541","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/comments?post=15541"}],"version-history":[{"count":0,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/15541\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/media?parent=15541"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/categories?post=15541"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/tags?post=15541"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/ppma_author?post=15541"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}